It’s only fair to share… Envudeucitinib CAS 2417135-66-9 MF C22H18[2]H6N6O3 MW426.5 g/mol N-[4-{2-methoxy-3-[1-(2H3)methyl-1H-1,2,4-triazol-3-yl]anilino}-5-(3,3,3-2H3)propanoylpyridin-2-yl] cyclopropanecarboxamide N-(4-(2-methoxy-3-(1-(trideuteriomethyl)-1,2,4-triazol-3-yl)anilino)-5-(3,3,3-trideuteriopropanoyl)pyridin-2-yl)cyclopropanecarboxamide N-[4-[2-methoxy-3-[1-(trideuteriomethyl)-1,2,4-triazol-3-yl]anilino]-5-(3,3,3-trideuteriopropanoyl)pyridin-2-yl]cyclopropanecarboxamideJanus kinase inhibitor, anti-inflammatory, Fronthera U.S. Pharmaceuticals, psoriasis, FTP 637 Envudeucitinib is an investigational new drug that is being evaluated for the treatment of psoriasis. It is a selective tyrosine kinase 2 (TYK2) inhibitor developed by Fronthera U.S. Pharmaceuticals LLC and now owned by Alumis, Inc. for …
Darbinurad
It’s only fair to share… Darbinurad CAS 1877347-38-0 MF C18H16N2O2S MW 324.4 g/mol [1-({[3-(4-cyanophenyl)pyridin-4-yl]sulfanyl}methyl)cyclopropyl]aceticacid 2-[1-[[3-(4-cyanophenyl)-4-pyridinyl]sulfanylmethyl]cyclopropyl]acetic acidurate transporter inhibitor, AYFFM7L5F0 Darbinurad is a investigational new drug that is being evaluated for the treatment of gout. It is a selective urate transporter 1 (URAT1) inhibitor that blocks the reabsorption of uric acid within the renal proximal tubule, thereby reducing serum uric acid concentrations.[1][2] Uric acid is the …
Imlunestrant
It’s only fair to share… Imlunestrant CAS 2408840-26-4 as tosylate: 2408840-41-3 (5R)-5-[4-[2-[3-(fluoromethyl)azetidin-1-yl]ethoxy]phenyl]-8-(trifluoromethyl)-5H-chromeno[4,3-c]quinolin-2-ol MF C29H24F4N2O3 MW 524.516 FDA 9/25/2025, Inluriyo, LY3484356, LY-3484356, To treat estrogen receptor-positive, human epidermal growth factor receptor 2-negative, estrogen receptor-1-mutated advanced or metastatic breast cancer with disease progression following at least one line of endocrine therapy Imlunestrant, sold under the brand name Inluriyo, is …
Dapolsertib
It’s only fair to share… Dapolsertib CAS 1616359-00-2 MF C15H18Br2N4O MW 446.14 g/mol 5,6-dibromo-4-nitro-2-piperidin-4-yl-1-propan-2-ylbenzimidazole 5,6-dibromo-4-nitro-2-(piperidin-4-yl)-1-(propan-2-yl)-1H-1,3-benzimidazoleserine/ threonine kinase inhibitor, antineoplastic Ryvu Therapeutics SA, MEN1703, SEL24-B489 Dapolsertib is an investigational new drug that is being evaluated for the treatment of cancer. It is dual inhibitor of PIM family of serine/threonine protein kinases and mutant forms of FMS-related tyrosine kinase 3 (FLT3) that is being developed …
Crelosidenib
It’s only fair to share… Crelosidenib CAS 2230263-60-0 7-{[(1S)-1-(4-{(1S)-1-[4-(prop-2-enoyl)piperazin-1-yl]-2-cyclopropylethyl}phenyl)ethyl]amino}-1-ethyl-1,4-dihydro-2Hpyrimido[4,5-d][1,3]oxazin-2-oneisocitrate dehydrogenase 1 (IDH1) inhibitor, antineoplastic MF C28H36N6O3 MW 504.6 g/mol Crelosidenib is an investigational new drug that is being evaluated for the treatment of cancer. It acts as a selective inhibitor of isocitrate dehydrogenase 1 (IDH1), an enzyme that plays a crucial role in cellular metabolism and is frequently mutated in various …
Copper (64Cu) adarulatide tetraxetan
It’s only fair to share… Copper (64Cu) adarulatide tetraxetan Adarulatide tetraxetan copper Cu-64 CAS 2841388-40-5 MF C76H10764CuN17O22, MF1,674.7 Cuprate(3-)-64Cu, [N-[2-[4,10-bis[(carboxy-κO)methyl]-7-(carboxymethyl)-1,4,7,10-tetrazacyclododec-1-yl-κN1,κN4,κN7,κN10 ]acetyl]-L-α-aspartyl-3-cyclohexyl-L-alanyl-L-phenylalanyl-D-seryl-D-arginyl-L-tyrosyl-L-leucyl-L-tryptophanyl-L-serinato(5-)]-, hydrogen (1:3) N-({4,10-bis[(carboxylato-κO)methyl]-7- (carboxymethyl)-1,4,7,10-tetraazacyclododecan-1-ylκ4 N1 ,N4 ,N7 ,N10}acetyl)-L-α-aspartyl-3-cyclohexyl-Lalanyl-L-phenylalanyl-D-seryl-D-arginyl-L-tyrosyl-L-leucylL-tryptophyl-L-serinecopper 2-[4-[2-[[(2S)-3-carboxy-1-[[(2S)-1-[[(2S)-1-[[(2R)-1-[[(2R)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(1S)-1-carboxy-2-hydroxyethyl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-cyclohexyl-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]amino]-2-oxoethyl]-7-(carboxylatomethyl)-10-(carboxymethyl)-1,4,7,10-tetrazacyclododec-1-yl]acetate;copper-64(2+)diagnostic imaging agent, QM8HMM6RJP AS ON JUNE2025 4.45 LAKHS VIEWS ON BLOG WORLDREACH AVAILABLEFOR YOUR ADVERTISEMENT join me on Linkedin Anthony Melvin Crasto Ph.D – India | LinkedIn join …
Claziprotamide
It’s only fair to share… Claziprotamide CAS 2361124-03-8, BBP 671 MF C19H20ClFN4O MW374.8 g/mol 1-[4-(6-chloropyridazin-3-yl)piperazin-1-yl]-2-(4-cyclopropyl-3-fluorophenyl)ethan-1-one 1-[4-(6-chloropyridazin-3-yl)piperazin-1-yl]-2-(4-cyclopropyl-3-fluorophenyl)ethan-1-onepantothenate kinases 1 and 3 (PanK1 and PanK3) positive allosteric modulator Claziprotamide is an investigational new drug that is being evaluated for the treatment of rare metabolic disorders such as pantothenate kinase-associated neurodegeneration (PKAN) and neurodegeneration with brain iron accumulation (NBIA). It acts as a positive allosteric modulator …
Camibirstat
It’s only fair to share… Camibirstat CAS 2671128-05-3 N-{(2S)-1-[(4-{6-[(2R,6S)-2,6-dimethylmorpholin-4-yl]pyridin-2-yl}-1,3-thiazol-2-yl)amino]-3-methoxy-1-oxopropan-2-yl}-1-(methanesulfonyl)-1H-pyrrole-3-carboxamideATPase inhibitor, antineoplastic MW C24H30N6O6S2 MF 562.7 g/mol Camibirstat is an investigational new drug that is being evaluated for the treatment of cancer. It is a small molecule that acts as a selective inhibitor of SMARCA2 and SMARCA4, which are key components of the SWI/SNF chromatin remodeling complex.[1] It is being developed by Foghorn Therapeutics.[2] Camibirstat …
Brimarafenib
It’s only fair to share… Brimarafenib CAS 1643326-82-2 MF C24H17F3N4O4 MW482.4 g/mol N-{(1S,1aS,6bS)-5-[(7-oxo-5,6,7,8-tetrahydro-1,8-naphthyridin-4-yl)oxy]-1a,6b-dihydro-1H-cyclopropa[b]benzofuran-1-yl}-N′-(2,4,5-trifluorophenyl)urearapidly accelerated fibrosarcoma (Raf) kinase inhibitor, Antineoplastic, MapKure, LLC, SpringWorks Therapeutics, BeiGene, BGB-3245, BGB 3245, GXS33OY2CB Brimarafenib is an investigational new drug that is being evaluated for the treatment of cancer. It targets the proto-oncogene BRAF with activating mutations BRAF mutations (such as V600E), non-V600 BRAF mutations, and RAF fusions.[1][2] …
Brezivaptan
It’s only fair to share… Brezivaptan CAS 1370444-22-6 ANC-501, THY-1773, TS-121, 575OB1CKN0 MF C25H30ClN5O3 MW 484.0 g/mol 2-[3-(3-chlorophenyl)-1-{4-[2-(morpholin-4-yl)ethyl]phenyl}-5-oxo-1,5-dihydro-4H-1,2,4-triazol-4-yl]-N-(propan-2-yl)acetamide 2-[3-(3-chlorophenyl)-1-[4-(2-morpholin-4-ylethyl)phenyl]-5-oxo-1,2,4-triazol-4-yl]-N-propan-2-ylacetamidevasopressin receptor antagonist Brezivaptan[1] (developmental code names ANC-501, THY-1773, TS-121) is an orally active, selective vasopressin V1B receptor antagonist which is under development by Taisho Pharmaceutical for the adjunctive treatment of major depressive disorder.[2][3][4] As of November 2022, it is in phase II clinical trials for this indication.[2][3][5] ANC-501 is under investigation in clinical trial NCT05439603 (ANC-501 in the Treatment …